AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie acquires Apogee for $10.9B to add zumilokibart, an immunology drug dosed 2–4 times yearly for inflammatory diseases. The deal signals pharma's trend toward consolidation via focused biotech acquisitions—key signal for partnership and M&A strategy.